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Perfluorooctanoic acid (PFOA, or C8) is a 
synthetic chemical that is used as a processing 
aid in the manufacture of fluoropolymers. 
Products made with fluoropolymers possess 
unique properties, including oil, stain, grease, 
and water repellency. These properties led 
to the widespread use of fluoropolymers in a 
number of products, including nonstick cook-
ware, weather- and stain-resistant clothing 
and textiles, building and construction mate-
rials, and electronics (Renner 2001).
The chemical structure of PFOA 
makes the compound extremely resistant 
to environmental and metabolic degrada-
tion. PFOA has been detected globally in 
the environment (Lau et al. 2007). It is well 
established that PFOA is readily absorbed via 
inhalation and ingestion. Routes of exposure 
in the general population remain unclear, 
although research suggests that diet is a 
potentially important source (Trudel et al. 
2008). PFOA is detected in the vast majority 
of serum samples from U.S. and world popu-
lations (Lau et al. 2007). Once absorbed, 
PFOA is eliminated from the human body 
very slowly. Estimates of the serum half-life 
of PFOA range from 2.3 years in residents 
of a contaminated community to 3.8 years 
in retired fluorochemical workers (Bartell 
et al. 2010; Olsen et al. 2007). Some evi-
dence suggests that PFOA concentrations in 
serum are declining, possibly due to reduc-
tions in use; however, the median serum 
concentrations remain around 4 µg/L in the 
U.S. population (Calafat et al. 2007a, 2007b; 
Olsen et al. 2007). PFOA exposure also has 
been linked to a variety of health impacts 
in animals, including increased cancer risk, 
adverse reproductive outcomes, and liver 
damage (Lau et al. 2004, 2007). Because of 
a lack of data, health impacts of exposure in 
humans remain largely unknown (Steenland 
et al. 2010).
In 2003, the U.S.  Environmental 
Protection Agency (EPA) began an enforceable 
consent agreement process with industry 
and other stakeholders to collect additional 
information for a PFOA risk assessment (U.S. 
EPA 2010a). The U.S. EPA and DuPont (the 
maker of Teflon) entered a memorandum of 
understanding (MOU) in November 2005 
as part of the risk assessment. Building on an 
agreement in place between the West Virginia 
Department of Environmental Protection 
and DuPont, the MOU required DuPont to 
conduct environmental sampling, including 
the monitoring of groundwater and surface 
waters around its Washington Works facility 
in Parkersburg, West Virginia, USA (U.S. 
EPA 2004a).
DuPont began using PFOA in the manu-
facture of Teflon at its Washington Works 
plant in the early 1950s. According to data 
provided by the company, emissions to air 
and the Ohio River reached a maximum 
in the late 1990s (Emmett et al. 2006; 
Paustenbach et al. 2007). The company 
reported a large reduction in these emissions 
in recent years (U.S. EPA 2010b). Previous 
research indicates that the primary source of 
exposure for individuals in the surrounding 
communities is contaminated groundwater 
that is used for drinking water (Emmett 
et al. 2006; Steenland et al. 2009). The 
groundwater in the area was contaminated 
via two main routes: PFOA released into 
the atmosphere was deposited onto soils and 
eventually leached downward into ground-
water, and PFOA was released directly into 
the Ohio River, which runs near the facil-
ity and is linked to the groundwater supply 
(Paustenbach et al. 2007).
In 2001, a group of residents in 
communities surrounding the facility filed 
a class action lawsuit against DuPont alleg-
ing health damages after PFOA was detected 
in public drinking water. The settlement 
established the C8 Health Project, a baseline 
survey conducted in 2005–2006 to investigate 
potential links between PFOA and human 
disease in the area surrounding the facility 
(Frisbee et al. 2009).
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Ba c k g r o u n d: The C8 Health Project was established in 2005 to collect data on perfluorooctanoic 
acid (PFOA, or C8) and human health in Ohio and West Virginia communities contaminated by a 
fluoropolymer production facility.
oB j e c t i v e: We assessed PFOA exposure via contaminated drinking water in a subset of C8 Health 
Project participants who drank water from private wells.
Me t h o d s : Participants provided demographic information and residential, occupational, and medi-
cal histories. Laboratory analyses were conducted to determine serum-PFOA concentrations. PFOA 
data were collected from 2001 through 2005 from 62 private drinking water wells. We examined 
the relationship between drinking water and PFOA levels in serum using robust regression meth-
ods. As a comparison with regression models, we used a first-order, single-compartment pharmaco-
kinetic model to estimate the serum:drinking-water concentration ratio at steady state.
re s u l t s: The median serum PFOA concentration in 108 study participants who used private wells 
was 75.7 µg/L, approximately 20 times greater than the levels in the U.S. general population but 
similar to those of local residents who drank public water. Each 1 µg/L increase in PFOA levels in 
drinking water was associated with an increase in serum concentrations of 141.5 µg/L (95% con-
fidence interval, 134.9–148.1). The serum:drinking-water concentration ratio for the steady-state 
pharmacokinetic model was 114.
co n c l u s i o n s: PFOA-contaminated drinking water is a significant contributor to PFOA levels in 
serum in the study population. Regression methods and pharmacokinetic modeling produced simi-
lar estimates of the relationship.
key w o r d s : drinking water, perfluorooctanoic acid (PFOA, or C8), pharmacokinetic model-
ing, private wells, serum. Environ Health Perspect 119:92–97 (2011).  doi:10.1289/ehp.1002503 
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Previous studies showed a significant 
association between living in an area with con-
taminated public drinking water and increased 
PFOA levels in serum using water-district–
level data (Emmett et al. 2006; Hölzer et al. 
2008; Steenland et al. 2009; Vieira et al. 2008. 
These studies are partially ecologic because 
the exposure variable is assigned at the group 
level, whereas other variables are assigned at 
the individual level (Björk and Strömberg 
2002; Webster 2000, 2002). In particular, 
previous studies provide information on serum 
concentration in relation to average exposure 
for populations serviced by the same water 
supply, but investigations into the relation-
ship between contaminated private household 
well water and serum levels are lacking. In the 
present analyses, we examined the relation-
ship between PFOA cocncentrations in serum 
and in drinking water using data collected 
from private drinking water wells contami-
nated by industrial emissions. By using data 
from private drinking water wells, we were 
able to quantify PFOA levels in the drinking 
water of C8 Health Project participants at 
the individual level. We assessed the relation-
ship using standard regression approaches; for 
comparison, we also used a pharmaco  kinetic 
model to explore the association between 
PFOA in drinking water and in serum lev-
els. Simple, single-compartment, first-order 
models have been applied previously to esti-
mate the serum concentration after expo-
sure from diet and drinking water (Fromme 
et al. 2007; Vieira et al. 2008). In the pres-
ent analyses, we used updated estimates of 
pharmacokinetic parameters to predict the 
serum:drinking-water concentration ratio. We 
compared the association between drinking-
water and serum PFOA concentrations from 
regression models with those obtained in 
pharmacokinetic analyses.
Materials and Methods
Study population. The C8 Health Project, 
a cross-sectional study of approximately 
69,000 adults, was conducted by Brookmar 
Inc. from August 2005 through August 
2006 (Frisbee et al. 2009). Participants lived 
in one of six public water districts in West 
Virginia and Ohio that surround DuPont’s 
Washington Works facility: Belpre, Little 
Hocking, Lubeck, Mason County, Pomeroy, 
and Tuppers Plains–Chester (Figure 1). 
Data were collected from each participant 
using questionnaires and clinical examina-
tions to obtain demographic information 
and residential, occupational, and medical 
histories (Frisbee et al. 2009). Concentrations 
of 10 perfluorinated compounds, including 
PFOA, were also determined in serum sam-
ples taken once from each participant between 
August 2005 and August 2006. Detailed 
analytic methods were described previously 
(Kuklenyik et al. 2004). Briefly, serum sam-
ples were analyzed using automated solid-
phase extraction coupled to reversed-phase 
high-performance liquid chromatography. 
The Institutional Review Board of 
Boston University Medical Center approved 
this research, and the participants provided 
informed consent to have their data used for 
research purposes.
Water monitoring was conducted 
by DuPont in public and private wells 
surrounding the Washington Works facility 
beginning in 2001. Private well monitoring 
reports contained PFOA measurements as 
well as the primary use of each well and the 
name and address of each well’s owner. These 
reports are available through the EPA (U.S. 
EPA 2004b). We linked well monitoring data 
for 62 private wells that were used primar-
ily for drinking water to C8 Health Project 
participants based on name and address. 
We also identified individuals who had the 
same last name and address as the well owner 
as family members. A total of 115 partici-
pants were included in the study. The num-
ber of samples taken in each well before the 
collection of serum samples varied. Although 
most wells were sampled just once, 11 of the 
62 private wells were sampled multiple times. 
Statistical analysis. In preliminary 
analyses, we identified several participants 
with serum-PFOA concentrations or well-
PFOA concentrations that were much greater 
than those of the other participants. For data 
with outliers, using standard least squares 
estimation is both inefficient and biased; 
regression coefficients are pulled toward outli-
ers, and estimates of the variance are artificially 
inflated, which can obscure outliers (Hampel 
et al. 1986). Therefore, we used robust 
regression methods to assess the relationship 
between PFOA concentrations in serum and 
Figure 1. Water districts included in the C8 Health Project and the locations of private drinking water wells 
that show the average PFOA concentration for each well.
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in drinking water. Robust regression provides 
stable results by limiting the influence of out-
liers and is generally less subject to bias than 
are standard least squares estimation meth-
ods (Hampel et al. 1986). Robust regressions 
were performed using Yohia’s MM estimator, 
which possesses high statistical efficiency and 
provides stable estimates of regression param-
eters when data include a relatively large per-
centage of outliers (Yohai 1987).
Additionally, because multiple indi-
viduals from the same family were included 
in the analyses, which violates the assump-
tion of independence for linear regression, 
we used generalized estimating equations 
(GEEs) in a second set of analyses to predict 
PFOA concentrations in serum from PFOA 
concentrations in drinking water. Using GEEs, 
we account for possible residual   within-family 
correlation and investigate the sensitivity of 
our results from the robust regression that 
includes multiple individuals from the same 
family in the analyses. GEEs and robust regres-
sions were preformed using SAS version 9.1 
(SAS Institute Inc., Cary, NC, USA).
Age and sex have been previously 
associated with serum PFOA levels in the 
population surrounding the Washington 
Works facility, as well as in other populations 
(Emmett et al. 2006; Hölzer et al. 2008; 
Steenland et al. 2009). Additionally, working 
at the Washington Works plant and growing 
one’s own vegetables were linked to increased 
PFOA levels in serum (Emmett et al. 2006; 
Steenland et al. 2009). We included these a 
priori variables in all statistical models. We 
also assessed a number of other variables that 
have been linked to serum PFOA levels: body 
weight, consuming bottled water (modeled 
as yes or no), smoking cigarettes, and drink-
ing alcohol (Emmett et al. 2006; Steenland 
et al. 2009). Only the a priori variables were 
included in the final models because the 
others did not materially alter the association 
between serum and well-PFOA levels (did not 
cause a change > 10% in the predicted contri-
bution of drinking water to serum).
For wells with multiple PFOA sampling 
events, we used the arithmetic average PFOA 
concentration in each well to predict serum 
levels in regression models. This method pro-
vided an estimate of the serum:drinking-water 
concentration ratio that is readily comparable 
to the results of a steady-state pharmacokinetic 
model that assumes that the concentration of 
PFOA in drinking water is constant over time 
(discussed in the next section). We also per-
formed an analysis using time-weighted water 
concentrations based on a non-steady-state 
pharmacokinetic model. In the main analyses, 
we included all individuals regardless of how 
long they had lived at their current residence. 
We also performed analyses investigating the 
sensitivity of our results to the residential 
duration at a particular well. By restricting the 
sample to long-term residents (> 15 years), we 
ensured that participants had been exposed 
to water from a specific well long enough for 
their serum levels to have reached steady state.
Pharmacokinetic models. Regression, 
after adjusting for other factors, provides 
us with an estimate of the change in serum 
concentrations per unit change in water con-
centration. For comparison with the regression 
analyses, we also predicted the ratio of serum 
to PFOA concentrations in drinking water 
using a simple first-order, single-compartment 
pharmacokinetic model. Bartell et al. (2010) 
previously demonstrated that the pharmaco-
kinetics of PFOA in humans is consistent 
with first-order elimination. Based on data 
that suggested that the duration of exposure 
to PFOA-contaminated drinking water in the 
study population is on the order of decades 
(Paustenbach et al. 2007), we assumed that 
levels of PFOA in serum had reached a steady-
state concentration. The ratio of steady-state 
serum PFOA concentration, Cs (micrograms 
per liter), to water concentration, Cw (micro-
grams per liter), was modeled using the fol-
lowing equation (Bartell 2003):
  C
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where f is the fraction of PFOA absorbed, Q 
is the daily water intake (liters per day), k is 
the first-order rate constant for PFOA elimi-
nation (day–1; k = 0.693/t1/2, where t1/2 is the 
half-life), and Vd is the apparent volume of 
distribution (liters).
Values for each parameter were obtained 
from a review of available animal and human 
PFOA pharmacokinetic data (Table 1). We 
assumed that 100% of ingested PFOA was 
absorbed based on animal data (Butenhoff et al. 
2004; Gibson and Johnson 1979; Hundley 
et al. 2006). Similar estimates of the fraction 
of PFOA absorbed in humans that are highly 
exposed to PFOA have been used previously 
(Thompson et al. 2010; Trudel et al. 2008). In 
previous pharmacokinetic analyses of PFOA 
(Vieira et al. 2008), we used a serum half-life 
of 3.8 years (1,388 days) based on a small study 
of retired fluorochemical production workers 
(Olsen et al. 2007). In the present analyses, we 
applied a more recent estimate of 2.3 years (840 
days) based on data from Bartell et al. (2010) 
collected in a subset of C8 Health Project 
participants. The volume of distribution (Vd) 
is a proportionality constant in pharmacoki-
netic modeling that relates the total amount 
of a chemical in the body to the concentra-
tion in plasma. We used a Vd for PFOA of 181 
mL/kg and 198 mL/kg for males and females, 
respectively, based on results from cynomolgus 
monkey experiments (Butenhoff et al. 2004). 
Thompson et al. (2010) proposed a similar 
Vd (170 mL/kg) using data from residents of 
two chronically exposed communities around 
DuPont’s Washington Works facility. Because 
the goal of our regression analysis was to use the 
serum and water data to estimate a steady-state 
ratio, and not the Vd , we used the Butenhoff 
estimate from monkeys in the pharmacoki-
netic model rather than the Thompson esti-
mate from the same community. We scaled 
the Vd to the sex and body weight of the study 
participants and used the median of the study 
population in pharmacokinetic models. Because 
water consumption data were unavailable, we 
used the U.S. EPA’s recommended average tap 
water intake rate for adults of 1.4 L/day, which 
includes water consumed from the tap as a bev-
erage or used in the preparation of foods and 
beverages (U.S. EPA 1997).
Results
Linking well-monitoring data to C8 Health 
Project participants, we were able to iden-
tify 115 individuals who used 62 different 
private wells for drinking water. Of these 
individuals, 4 (3.5%) were missing data 
(PFOA levels in serum: n = 1, body weight: 
n = 2, race/ethnicity: n = 1) and were 
excluded from the analyses. We also excluded 
vegetarians (n = 2) and nonwhite partici-
pants (n = 1) because the numbers were too 
small to adequately control for these vari-
ables. Our final sample consisted of 108 par-
tici  pants. Serum PFOA levels ranged from 
0.9 to 4751.5 µg/L, with a median concentra-
tion of 75.7 µg/L (mean ± SD, 177.3 ± 499.7 
µg/L). As reported previously in the larger 
C8 Health Project sample (Steenland et al. 
2009), individuals who grew their own vege-
tables and who were employed at DuPont 
had higher median serum PFOA concentra-
tions (Table 2). PFOA concentrations were 
higher among older (> 65 years) and heavier 
(> 80 kg) participants, but the differences were 
not statistically significant (Table 2).
Figure 1 shows the well locations and the 
corresponding average PFOA concentrations. 
The number of participants using each well 
Table 1. Pharmacokinetic parameter values and sources.
Parameter Symbol Value Data source
Water intake Q 1.4 L/day U.S. EPA 1997
Fraction of PFOA absorbeda f 100% Gibson and Johnson 1979
Half-life t1/2 2.3 years, 840 days Bartell et al. 2010
Volume of distributiona Vd Male, 181 mL/kg; Female, 198 mL/kg; 
multiplied by individual body weight
Butenhoff et al. 2004
aBased on animal data.Exposure to PFOA via drinking water
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ranged from 1 to 4. The median PFOA 
concentration in drinking water wells included 
in our analyses was 0.2 µg/L (mean ± SD, 
0.8 ± 1.9 µg/L). Although the median was 
below the U.S. EPA provisional health 
advisory level of 0.4 µg/L, many participants 
had drinking water levels that exceeded the 
advisory level (U.S. EPA 2009). We found 
considerable variability between wells, with 
PFOA concentrations ranging from below the 
limit of quantification (LOQ = 0.006 µg/L) 
farthest from the Washington Works facil-
ity to 13.3 µg/L closest to the facility. One 
sample was reported below the LOQ and 
was assigned the LOQ (0.006 µg/L) in the 
analyses. Multiple samples were taken from 11 
wells that were used by 19 study participants. 
In general, we did not find an overall trend 
from 2001 to 2005 in the concentrations of 
PFOA in private drinking water. Although 
PFOA concentrations in each well appeared 
to fluctuate by season, these differences may 
be due to seasonal changes in precipitation. 
PFOA concentrations measured in 2004 and 
2005 for a subset of wells measured seasonally 
are shown in Supplemental Material, Figure 1 
(doi:10.1289/ehp.1002503).
Regression results. We examined the shape 
of the relationship between serum-PFOA con-
centration and average drinking water PFOA 
concentration using a locally weighted regres-
sion smoother (LOESS) in S-Plus (version 8.0; 
Tibco Software, Inc., Palo Alto, CA, USA). 
Visual inspection of a plot of the smoothed 
data indicated that the association between 
serum and drinking water PFOA levels could 
be estimated as a linear trend (data not shown), 
as suggested by the pharmacokinetic model 
(Equation 1). We therefore included the aver-
age drinking water PFOA concentration as 
a linear predictor of nontransformed serum 
PFOA concentrations in regression models. 
In the adjusted robust regression models each 
micrograms per liter increase in drinking water 
PFOA concentration was associated with a 
141.5 µg/L [95% confidence interval (CI) = 
134.9–148.1] increase in serum concentra-
tions. Table 3 presents effect estimates for 
other variables included in the model. Growing 
one’s own vegetables, being male, and being 
employed at DuPont were associated with 
elevated serum PFOA levels; however, asso-
ciations did not reach statistical significance 
at the 0.05 level. The estimated background 
serum level in this population after account-
ing for known sources was 7.4 µg/L (Table 3). 
Additionally, we investigated differences in the 
serum:drinking-water concentration ratio in 
males and females. When we stratified by sex, 
we observed very similar ratios in both sexes. 
Accordingly, we did not observe a significant 
(p-value < 0.05) sex-by-water concentration 
interaction (data not shown) when we included 
an interaction term in the models.
Robust regression analyses revealed six out-
liers (observations for which the standardized 
residual was > 3). For these individuals, the pre-
dicted values for serum PFOA concentrations 
using regression parameters underestimated or 
overestimated observed concentrations (stan-
dardized residuals, 3.0–44.5). In the analyses 
using GEEs, we observed a small within-  family 
correlation of serum PFOA levels of 0.1. 
Compared with the results of the robust regres-
sion, GEE analyses that excluded outliers pro-
duced a very similar estimate of effect (β) for 
each 1 µg/L increase in PFOA concentration 
(β = 141.8 µg/L; 95% CI, 134.3–149.4 µg/L) 
in drinking water. When we included outliers 
in the GEE, the estimate of the association 
between PFOA levels in serum and in drinking 
water was much larger. The inclusion of one 
participant in particular, with the highest 
PFOA concentrations in serum and drinking 
water in the population, increased the estimate 
of effect to 232.7 µg/L (95% CI, 200.9–264.5 
µg/L). We could not identify a plausible expla-
nation for this participant’s extreme serum 
concentration using available data (the par-
ticipant did not report being employed in the 
fluorochemical industry). Increased water con-
sumption in this individual may have resulted 
in the extreme concentration; however, data 
were not available to evaluate this hypothesis.
When we restricted our analyses to 
individuals with a residency > than 15 years, 
our results were similar (β = 140.2 µg/L; 
95% CI, 132.1–148.4 µg/L; n = 67). We 
considered other residential duration restric-
tions (2, 5, 10, and 20 years), but restric-
tions had little effect on the magnitude of 
the association between serum and drink-
ing water. We also excluded participants 
who were ever employed at the Washington 
Works facility, because these individuals may 
have had other significant sources of expo-
sure. Again, the association between drink-
ing water levels and serum was similar when 
we excluded these individuals. Additionally, 
excluding participants who reported consum-
ing bottled water (n = 6) from analyses had 
little effect on the magnitude of the associa-
tion between serum and drinking water.
Comparison of pharmacokinetic and 
regression results. Using the simple steady-
state first-order pharmacokinetic model 
(Equation 1) with a median Vd of 15,000 
mL in the study population after scaling 
for the body weight and sex of study par-
ticipants, we obtained a serum:drinking-
  water concentration ratio of 114. This ratio is 
similar to the ratio of 141.5 that was derived 
from regressing serum concentrations versus 
water concentrations.
Discussion
Serum PFOA concentrations in users of 
private wells in the area surrounding DuPont’s 
Washington Works facility were much greater 
than those observed in the general U.S. popu-
lation and were comparable to what has been 
observed in the study area previously (Emmett 
et al. 2006; Steenland et al. 2009; Vieira et al. 
2008). Private drinking water wells in the area 
were contaminated with PFOA, with levels 
in some wells being much greater than those 
observed in public drinking water supplies in 
the same area, which ranged from 0.03 µg/L 
in Mason County to 3.5 µg/L in Little 
Hocking (Emmett et al. 2006; Steenland et al. 
2009). Using data from private wells, we had 
a large number of individual exposure levels 
Table 2. Selected population characteristics, serum PFOA concentrations, and statistical significance of 
difference.
Characteristic n (%)
Median serum PFOA 
[μg/L (interquartile range)] p-Value
Total population 108 (100) 75.7 (31.5–130.5)
Male 51 (47.2) 82.2 (45.9–164.3) 0.10
Female 57 (52.8) 68.1 (21.0–115.5)
Grow own vegetables
No 64 (59.3) 50.7 (24.9–107.3) < 0.001
Yes 44 (40.7) 91.2 (57.0–145.2)
Employed at DuPont
No 94 (87.0) 67.6 (72.2–102.4) 0.11
Yes 14 (13.0) 87.1 (27.4–145.1)
Age (years)
≤ 65  63 (58.3) 59.8 (20.6–115.9) 0.35
> 65  45 (42.7) 84.9 (49.0–145.1)
Body weight (kg)
≤ 80 50 (46.3) 63.5 (31.5–107.7) 0.64
> 80 58 (53.7) 81.2 (30.1–177.4)
Table 3. Adjusteda robust regression model of 
serum PFOA.
Covariate β-Coefficient (95% CI)
Intercept 7.4 (–9.8 to 24.4)
Well PFOA 141.5 (134.9 to 148.1)
Males 18.8 (–1.6 to 39.1)
Age > 65 years –4.2 (–24.2 to 15.9)
Grow own vegetables 18.4 (–1.3 to 38.1)
Employed at DuPont 5.9 (–24.1 to 36.2)
aThe inclusion of other covariates (body weight, bottled 
water consumption, cigarette smoking, and alcohol con-
sumption) did not alter the main associations.Hoffman et al.
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and were able to assess a wide range of expo-
sures to PFOA via drinking water.
The results of the regression analyses are 
consistent with a strong association between 
PFOA levels in serum and PFOA concentra-
tions in drinking water. We found little dif-
ference in the association between serum and 
drinking water PFOA concentrations when 
we limited our analyses to 67 individuals who 
were long-term residents.
The serum:drinking-water concentration 
ratio of 141.5, which was estimated using 
regression analysis, was similar to ratios 
obtained in previous partially ecologic analy-
ses (Emmett et al. 2006; Vieira V, Webster T, 
Bartell S, Steenland K, Savitz D, Fletcher T, 
unpublished data). In our previous work in 
the study area, we found serum:drinking-
water concentration ratios in public water 
districts ranging from 59 to 411 (Vieira V, 
Webster T, Bartell S, Steenland K, Savitz D, 
Fletcher T, unpublished data). In Little 
Hocking, Ohio, near the Washington Works 
facility, Emmett et al. (2006) estimated a 
water concentration ratio of 105 in an analy-
sis of public water consumers. Additionally, 
in a small sample of private well users (n = 6), 
serum:water concentration ratios ranged from 
142 to 855 (Emmett et al. 2006).
The steady-state serum:drinking-water 
concentration ratio of 114 obtained from 
pharmacokinetic modeling was close to the 
estimate of effect (141.5) obtained from 
regression analyses. This result suggests that 
the pharmacokinetic model provides a reason-
able estimate. We used a serum PFOA half-life 
based on data that Bartell et al. (2010) col-
lected in a subset of C8 Health Project partici-
pants with exposure levels and patterns similar 
to the participants in our analyses. Using the 
half-life estimate from Olsen et al. (2007) 
of 3.8 years increased the serum:drinking-
water ratio to 188. Other pharmacokinetic 
parameters that we used were more uncertain, 
particularly the volume of distribution, which 
we estimated based on animal data (Butenhoff 
et al. 2004). A recent study by Thompson 
et al. (2010) estimated a very similar Vd (170 
mL/kg) based on data from community resi-
dents; using the Vd from that study produced 
a similar serum:drinking-water concentra-
tion ratio of 126. Based on data from sub-
chronic toxicity studies in monkeys, however, 
Washburn et al. (2005) recommended using a 
volume of distribution that was a factor of 10 
higher than the Butenhoff et al. (2004) ratio 
that we used in our analyses. If we had used 
their volume of distribution, our ratio would 
have been reduced by an order of magnitude. 
Further research is needed on the volume 
of distribution of polyfluoroalkyl chemicals 
in humans. Additionally, in the absence of 
consumption data for each individual, we 
used the U.S. EPA estimated average daily 
tap water consumption value of 1.4 L/day; 
however, water consumption in the study 
population likely varied (U.S. EPA 1997). We 
believe that the difference in serum:drinking-
water concentration ratio estimates from 
regression and pharmacokinetic models may 
be explained by these uncertainties.
As reported previously for C8 Health 
Project participants, we observed a posi-
tive association between serum PFOA lev-
els and growing one’s own vegetables after 
adjusting for water concentration, suggest-
ing that consuming locally grown food may 
be an important source of exposure in this 
population (Bartell et al. 2010; Steenland 
et al. 2009). The background serum PFOA 
concentration predicted in regression anal-
yses (7.4 µg/L) is greater than background 
levels previously reported in the U.S. popu-
lation [geometric mean, 3.8 µg/L (Calafat 
et al. 2007b); arithmetic mean, 4.3 µg/L 
(Centers for Disease Control and Prevention 
2007)]. These results suggest that there may 
be other sources of PFOA exposure in the C8 
Health Project population that we did not 
include in the model or that random expo-
sure misclassification may be inflating the pre-
dicted background levels for this population. 
Other potentially important sources of PFOA 
exposure in this population include water 
consumption at work, school, or religious 
and social organizations frequented by study 
participants. Although the release of PFOA 
from the Washington Works facility has been 
reduced (U.S. EPA 2010b), PFOA may still 
be present in indoor environments and may 
contribute an additional source of exposure 
for residents. Data were not available to test 
hypotheses on these exposure sources.
Our analyses are limited by our steady-
state assumption and reliance on a single 
measurement of serum levels and, in most 
cases, a single measurement of drinking water 
PFOA levels. For a small number of individuals 
with multiple well measurements, we con-
sidered variability in well measurements in a 
sensitivity analysis using a time-weighted well 
concentration rather than an arithmetic aver-
age to predict serum PFOA concentrations 
[see Supplemental Material (doi:10.1289/
ehp.1002503)]. Although we found some 
seasonal variability from 2001 to 2005, on 
average PFOA concentrations in the wells 
were fairly stable, and we found no long-term 
trend during this time period. Consequently, 
predicted serum concentrations that accounted 
for variation in PFOA concentrations in wells 
were similar to those obtained using simple 
steady-state models (data not shown).
Despite these limitations, our analyses 
have a number of strengths. We were able to 
link PFOA measurements in drinking water 
to a relatively large number of individual 
study participants who consumed private well 
water. The extensive questionnaire (Frisbee 
et al. 2009) administered as part of the C8 
Health Project allowed us to consider a num-
ber of potential confounders in the associa-
tion between PFOA levels in serum and in 
drinking water (including age, sex, growing 
one’s own vegetables, body weight, bottled 
water consumption, cigarette smoking, and 
alcohol consumption). Unlike previous 
assessments, which used water samples from 
public water supplies, we used drinking water 
samples from the participants’ wells, which 
increased the variability of exposure measures. 
Additionally, available residential history 
information allowed us to consider differences 
in long and short-term residents using con-
taminated wells for drinking water.
Conclusions
Private drinking water wells in West Virginia 
and Ohio communities surrounding the 
DuPont Washington Works facility are 
contaminated with PFOA. Concentrations 
in private wells are, in some cases, much 
greater than those observed in area public 
water districts. For private well users, adjusted 
regression analyses indicate that PFOA levels 
in drinking water are a significant predictor of 
PFOA levels in serum. The regression analysis 
predicted a 141.5 µg/L increase in serum lev-
els for each 1 µg/L increase in drinking water 
PFOA—a very similar result to the 114 µg/L 
in serum for each 1 µg/L predicted in steady-
state pharmacokinetic models. These results 
may also be applicable in other areas with 
point-source PFOA contamination.
co r r e c t i o n
In the manuscript originally published 
online (second paragraph of “Results”), the 
U.S. EPA provisional health advisory level 
for PFOA was given as 0.04 µg/L; how-
ever, this level is actually 0.4 µg/L. Thus, 
the median PFOA concentration found 
in the present study was “below” instead 
of “much greater than” the U.S. EPA pro-
visional health advisory level. It has been 
corrected here.
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